BioSpace News Archive

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that it will release its second-quarter 2022 financial results before the stock market opens on Tuesday, August 2, 2022, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.

MAKO Medical Laboratories , a national reference laboratory, today announced it has validated a PCR-based monkeypox-specific assay developed by Thermo Fisher Scientific.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that two executive team members will participate and present at the World Orphan Drug Congress, taking place July 11-13, at Hynes Center in Boston.

Samsung Biologics, the world’s leading contract development and manufacturing organization, published its second annual ESG Report, reflecting the company’s sustainability efforts in 2021 to address a wide range of environmental, social, and governance activities related to its business.

KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.

Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2022 and reiterated full year guidance.

New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS.

Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., president and CEO of Opus, will present at the Ophthalmology Innovation Source (OIS) Retina Innovation Summit 2022 on Wednesday, July 13, 2022, in New York.

Iterum Therapeutics plc announced today that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) under the special protocol assessment (“SPA”) process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”).